Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Synact Pharma announces outcome in the exercise of warrants, will receive approximately MSEK 32.4

On Wednesday, July 22, 2020, the exercise period for SynAct Pharma AB's (“SynAct” or “the Company”) warrants of series TO 2 (“TO 2”) ended. A total of 4,839,860 warrants of series TO 2 were exercised, corresponding to a subscription rate of approximately 98.95 percent of TO 2. SynAct is thus provided with a total of approximately MSEK 32.4 before issue costs. With the issue proceeds, the Company has secured the capital needed to finance several important milestones, such as demonstrating Proof-of-Concept for phase II studies with AP1189 within RA and NS.CEO Jeppe Øvlesen comments: “I

Scout Gaming launches 1 Million Euro Fantasy Premier League Season Game

As the leading B2B fantasy sports provider, Scout Gaming Group is following up last year’s “quarter of a mill” Premier League Season Game by offering €1,000,000 guaranteed prize pool for this season. With 50,000 available seats at €25 each, the competition promises to pay out 1,250 prizes, with the 1st place securing €200,000. The tournament will be available for Scout Gaming’s clients in the world-wide network.Scout Gaming’s seasonal game has similarities to the popular official Fantasy Premier League game with regards to budget, number of players, and some of the scoring rules. There are

alquence recommended for approval in the EU by CHMP for chronic lymphocytic leukaemia

27 July 2020 07:10 BST Calquence recommended for approval in theEU by CHMP for chronic lymphocytic leukaemia Recommendation based on two Phase III trials demonstrating superior progression-free survival across multiple settings while maintaining favourable tolerability AstraZeneca's Calquence (acalabrutinib) has been recommended for marketing authorisation in the European Union (EU) for the treatment of adult patients with chronic lymphocytic leukaemia (CLL), the most common type of leukaemia in adults.[1] The Committee for Medicinal Products for Human Use (CHMP) of the

Press Release: Awarded grant to develop a novel electrolyser stack to enable lower cost hydrogen generation

(Oslo, 27 July, 2020) Proton Energy Systems, Inc. (dba “Nel Hydrogen US”), a wholly owned subsidiary of Nel ASA (Nel, OSE:NEL), has been awarded a $4.4 million grant by the Department of Energy (DOE) for development of advanced components and manufacturing methods to enable low cost hydrogen from electrolysis. The purpose of the project is to leverage the DOE National Lab capabilities to develop advanced cell configurations which optimize interactions between components such as flow and conductivity, and translate those configurations to low cost manufacturing methods in collaboration

Vicore Pharma doses first COVID-19 patient in the ATTRACT study in India

Gothenburg, July 27, 2020 – Vicore Pharma Holding AB (publ), a pharmaceutical company dedicated to developing innovative medicines for rare lung disorders, today announces that the first patient in the ATTRACT study has been dosed in India at Ruby Hall Clinic in Pune.Ruby Hall Clinic, Pune, has dosed the first patient, two more sites are fully approved and are also expected to start enrollment this week and five more sites are being initiated. “With 40,000 new cases per day and still increasing, the prerequisites for a COVID-19 trial are dramatically different in India versus the UK”, says

Imfinzi recommended for approval in the EU by CHMP for extensive-stage small cell lung cancer

27 July 2020 07:05 BST Imfinzi recommended for approval in the EU byCHMP for extensive-stage small cell lung cancer Only PD-1/PD-L1 immunotherapy to demonstrate a significant survival benefit and improved response rate in combination with a choice of chemotherapies AstraZeneca's Imfinzi (durvalumab) has been recommended for marketing authorisation in the European Union (EU) for the 1st-line treatment of adults with extensive-stage small cell lung cancer (ES-SCLC) in combination with a choice of chemotherapies, etoposide plus either carboplatin or cisplatin. SCLC is a highly

AstraZeneca and Daiichi Sankyo enter collaboration to develop and commercialise new antibody drug conjugate

This announcement contains inside information 27 July 2020 07:00 BST AstraZeneca and Daiichi Sankyo enter collaboration todevelop and commercialise new antibody drug conjugate Potential new medicine DS-1062 could redefine treatmentstandards in lung, breast and multiple other cancers AstraZeneca has entered into a new global development and commercialisation agreement with Daiichi Sankyo Company, Limited (Daiichi Sankyo) for DS-1062, Daiichi Sankyo's proprietary trophoblast cell-surface antigen 2 (TROP2)-directed antibody drug conjugate (ADC) and potential new medicine for

Lantmännen launches fully-soluble PromOat Instant oat beta-glucan for supplements and beverages

Lantmännen Functional Foods is now launching PromOat Instant - the first oat beta-glucan that is 100% soluble in water. PromOat Instant, which is is extracted from Swedish, GMO-free, wholegrain oats, addresses major health issues such as heart disease and diabetes.Lantmännen, the Swedish agricultural cooperative, announces the launch of PromOat Instant, a fully-soluble version of its oat beta-glucan ingredient, PromOat. Designed especially for use in consumer applications, such as nutritional supplements and powdered beverages. PromOat Instant is extracted from Swedish, GMO-free, wholegrain

Read original

Change of Adviser

Faron Pharmaceuticals Oy (“Faron” or the “Company”)Company announcement, 27 July 2020 at 9.00 AM (EET) TURKU - FINLAND, 27 July 2020 - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, is pleased to announce that Cairn Financial Advisers LLP has been appointed as Nominated Adviser to the Company with immediate effect.  Panmure Gordon (UK) Limited continues to act as the Company’s Broker. For further information, please contact: Faron Pharmaceuticals Oy Dr Markku Jalkanen, Chief Executive Officer investor.relations@faron.

Changes in Outokumpu’s Leadership Team

Outokumpu OyjStock exchange releaseJuly 27, 2020 at 9.00 am EESTChanges in Outokumpu’s Leadership Team Maciej Gwozdz, President, business area Europe has decided to resign from Outokumpu to take a new position in another company. He will continue to work in Outokumpu in his current position until the end of September. His successor will be appointed in due course. Says CEO Heikki Malinen: “Mac has had important roles in Outokumpu during the past four years, first as head of business area Europe’s operations and since 2018 as President of the business area. During this period,

Notice for the Annual General Meeting of Shareholders in Momentum Group AB (publ) on 31 August 2020

The shareholders in Momentum Group AB (publ), corporate registration number 559072-1352 (“Momentum Group” or the “Company”), are hereby convened to the Annual General Meeting of Shareholders at 4:00 p.m. CEST on Monday, 31 August 2020 at IVA’s Conference Centre, Grev Turegatan 16, Stockholm, Sweden. The doors will open at 3:30 p.m. CEST. COVID-19 PANDEMIC MEASURES Momentum Group will take precautionary measures in preparation for the 2020 Annual General Meeting given the increased risk for the spread of infection in Sweden, according to the Public Health Agency of Sweden. The aim

YIT and OP-Rental Yield special fund to establish a company for housing investments

YIT Corporation                  Investor news                    July 27, 2020, at 9:00 a.m.YIT and OP-Rental Yield special fund to establish a company for housing investments YIT and OP-Rental Yield special fund have agreed to establish a company investing in rental apartments. In the same connection, YIT has agreed on the sale of eight rental apartment buildings to the company. The investment value of the projects is approximately EUR 130 million, and YIT’s share of the joint investment will be 40%. The buildings will have a total of over 600 apartments, and the construction will

Wulff Group Plc’s Half-Year Financial Report for January 1 – June 30, 2020

HALF-YEAR FINANCIAL REPORT  JULY 27, 2020 AT 9.00 A.M.This is a summary of Wulff Group Plc’s half-year financial report for January-June 2020. Wulff Group’s half-year financial report as a whole is attached as a PDF file to this stock exchange release and it is also available on the company’s website www.wulff.fi.   Adaptability generated profitable business even in remote offices 1.4.–30.6.2020 BRIEFLY · Net sales totalled EUR 15.1 million (15.4), decrease of 2.0% · EBITDA and comparable EBITDA grew to EUR 1.7 million (0.9) · Operating profit and comparable operating

Notification in accordance with the Finnish Securities Market Act Chapter 9 § 5: BlackRock, Inc.’s holding in Wärtsilä Corporation

Wärtsilä Corporation, Stock exchange release, 27 July 2020 at 9:00 am EESTNotification in accordance with the Finnish Securities Market Act Chapter 9 § 5: BlackRock, Inc.’s holding in Wärtsilä CorporationBlackRock, Inc. has informed Wärtsilä Corporation that it has crossed below the 5% disclosure limit on shares and voting rights on 23 July 2020. Total position of BlackRock, Inc. and its funds subject to the notification: % of % of shares Total of Total number of shares shares and voting both in % and voting rights of

Recipharm AB publishes its interim report for the second quarter 2020

April – June 2020 · Net sales amounted to SEK 3,081 million (1,867), an increase of 65% · EBITA increased by 83% and amounted to SEK 423 million (232) corresponding to an EBITA margin of 13.7% (12.4) · Strong profitable organic growth · Net positive COVID-19 impact on sales and earnings · Operating profit (EBIT) amounted to SEK 340 million (171) and was affected by non-recurring items of SEK +17 million (0) · Profit after tax amounted to SEK 300 million (94) corresponding to a net margin of 9.7% (5.0) · Earnings per share amounted to SEK 4.22 (1.38) before dilution

Metso Outotec publishes positive profit warning

Metso Outotec Corporation, Insider information, on July 27, 2020, at 8:30 a.m. EESTMetso Outotec publishes preliminary information on its second-quarter results, which according to the information available to the company, seem to be better than market expectations. The good development during the second quarter has resulted from the mining industry being relatively less affected by Covid-19, healthy product margins and delivery capabilities as well as rapid and successful cost saving actions. These had a positive impact to sales and adjusted EBITA. Operating profit (EBIT), however, has

ABS and SHI Target End-to-End 3D Model-Based Class Process

Successive JDPs Aim to Deliver Next Generation Digital Class(BUSAN) ABS and Samsung Heavy Industries (SHI) are working together to deliver Korea’s first end-to-end 3D model-based Class process, encompassing engineering and survey.ABS and SHI celebrated completion of a landmark 3D model-based Review project by signing a new joint development project (JDP) to develop 3D model-based Surveys.The signing follows ABS and SHI’s development of a paperless 3D model-based design and review process, completing a JDP signed at Gastech in Houston, Texas, in September 2019. The project moves into the

Multiconsult wins new hydropower contracts in Tanzania

Tanzania Electric Supply Company Limited (TANESCO) has selected Multiconsult Norge AS with Norplan Tanzania Ltd (49% owned) and Tanzania Photomap Ltd as subcontractors, to provide consultancy services for the Rumakali Hydropower and Transmission Line Project and for Ruhudji Hydropower and Transmission Line Project in Tanzania. The total contract value for Multiconsult will be approximately NOK 55 million.Work will begin immediately and is planned to be completed in Q2 2021. The United Republic of Tanzania through TANESCO will fund the review and update of the feasibility study,

Stora Enso - White color

Stora Enso’s long-term financial targetsStora Enso has revised its long-term financial targets. There are new Group level targets for growth and return on capital employed (ROCE). The divisional targets for Packaging Solutions and Forest will also change. Also, dividend policy is updated to distribute 50% of EPS excluding fair valuation over the cycle. Other targets remain unchanged.  KPI New target Comparison to old targetsGroup Dividend* To

Leading Edge Materials Announces Results of AGM

Vancouver, July 24, 2020 /CNW/ – Leading Edge Materials Corp. (“Leading Edge Materials” or the “Company”) (TSXV: LEM) (Nasdaq First North: LEMSE) (OTCQB: LEMIF) announces the voting results from the Company’s Annual General of Shareholders held on Friday, July 24, 2020 (the “Meeting“). A total of 21,776,332 common shares were voted, representing 19.02% of the Company’s issued and outstanding common shares. Shareholders voted in favour of setting the number of directors at three (3) and for the re-election of all director nominees. The percentage of votes cast for each director is as

Kongsberg Automotive ASA – Results of subsequent offering and issuance of shares in the long term incentive plan employee offering

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, JAPAN, HONG KONG, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER TO BUY, SELL OR SUBSCRIBE FOR ANY SECURITIES DESCRIBED HEREIN. Reference is made to previous announcements regarding a subsequent offering in Kongsberg Automotive ASA (the "Company") with gross proceeds of up to NOK 300 million by issuance of up to 3,000,000,000 new shares at a subscription

Publication of a Prospectus

Regulatory Announcement   Royal Bank of Canada July 24, 2020 Publication of Prospectus  Not for release, publication or distribution, directly or indirectly, in or into the United States. The following prospectus has been approved by the Financial Conduct Authority and, along with the documents incorporated by reference therein, is available for viewing:  Prospectus dated July 24, 2020 relating to the Programme for the €60,000,000,000 Global Covered Bond Programme of Royal Bank of Canada, unconditionally and irrevocably guaranteed as to payments by RBC Covered Bond

Publication of a Prospectus

Regulatory Announcement   Royal Bank of CanadaJuly 24, 2020 Publication of Prospectus  Not for release, publication or distribution, directly or indirectly, in or into the United States. The following prospectus has been approved by the Financial Conduct Listing Authority and, along with the documents incorporated by reference therein, is available for viewing:  Notes Base Prospectus dated July 24, 2020 relating to the Programme for the Issuance of Securities of Royal Bank of Canada which was approved by the Financial Conduct Listing Authority on July 24, 2020. The

EAB GROUP PLC: ACQUISITION OF OWN SHARES 24.07.2020

EAB GROUP PLC NOTIFICATION 24.07.2020 at 18:30 EAB GROUP PLC: ACQUISITION OF OWN SHARES 24.07.2020 Date 24.07.2020Exchange transaction BuyShare class EABAmount 114Average price/share 2.3000 EURHighest price/share 2.3000 EURLowest price/share 2.3000 EURTotal price 262.20 EUR The shares held by EAB Group Plc on 24.07.2020: EAB 30,007 On behalf of EAB Group Plc  Skandinaviska Enskilda Banken AB (Publ) Antti Salakka         Mikko Virtanen For more information, please

There are no items matching the current filter
There are no more items matching the current filter
Back to top